Iconic Labs PLC
("Iconic" or the "Company")
Conversion of Notes and Allotment of Shares
The following amendments have been made to the "Conversion of Notes and Allotment of Shares" announcement released on 18 September 2023 at 07:37a.m. under RNS No. 7444M.
The figure for the number of shares for which application is being made referenced in the third paragraph should be 236,406 new Ordinary Shares and the two figures for the total issued share capital and total voting rights in the fourth paragraph, should both be 5,239,681. All other details remain unchanged. The full amended text is shown below.
Iconic Labs PLC (LSE:ICON), announces that it has received a valid Conversion Notice from the European High Growth Opportunities Securitization Fund.
The Conversion Notice was dated 14 September 2023 and provides for 30 Convertible Notes to be converted into 236,406 ordinary shares of £0.1 in the Company ("Ordinary Shares") at a conversion price of £0.1269 at the aggregate principal amount of £30,000.
Application is being made for 236,406 new Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange which is expected to be on or around 22 September 2023. These shares rank pari passu with the existing Ordinary Shares of the Company.
Following the issue of these shares, the Company's issued ordinary share capital shall consist of 5,239,681 Ordinary Shares. The figure of 5,239,681 represents the total voting rights in the Company and should be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance & Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
For any further information or enquiries please contact:
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
